Literature DB >> 10873172

Neonatal group B streptococcal disease associated with infected breast milk.

W J Olver1, D W Bond, T C Boswell, S L Watkin.   

Abstract

Premature triplets each developed late onset group B streptococcal disease over a period of nine weeks. The source of the organism appeared to be expressed maternal breast milk, in the absence of clinical mastitis. Asymptomatic excretion of group B streptococcus in breast milk may be an under-recognised cause of neonatal infection.

Entities:  

Mesh：

Year:  2000        PMID： 10873172      PMCID： PMC1721104          DOI： 10.1136/fn.83.1.f48

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN： 1359-2998            Impact factor:   5.747


  6 in total

1.  Recurrent group B streptococcal disease in an infant associated with the ingestion of infected mother's milk.

Authors:  J F Kenny
Journal:  J Pediatr       Date:  1977-07       Impact factor: 4.406

2.  Multiple group B streptococcal infections in a premature infant: eradication of nasal colonization with rifampin.

Authors:  D D Millard; M E Bussey; S T Shulman; R Yogev
Journal:  Am J Dis Child       Date:  1985-10

3.  Group B streptococci in the milk of lactating mothers.

Authors:  V Kubín; H Mrastíková; M Paulová; J Motlová; J Franĕk
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-06

4.  Recurrent group B streptococcal disease in infants: Who should receive rifampin?

Authors:  J T Atkins; G P Heresi; T M Coque; C J Baker
Journal:  J Pediatr       Date:  1998-03       Impact factor: 4.406

5.  Unusual occurrence of an epidemic of type Ib/c group B streptococcal sepsis in a neonatal intensive care unit.

Authors:  F J Noya; M A Rench; T G Metzger; G Colman; J Naidoo; C J Baker
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

6.  Analysis of DNA restriction fragment length polymorphism extends the evidence for breast milk transmission in Streptococcus agalactiae late-onset neonatal infection.

Authors:  E Bingen; E Denamur; N Lambert-Zechovsky; Y Aujard; N Brahimi; P Geslin; J Elion
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226
  6 in total
  7 in total

1.  Horizontal transmission of group B streptococcus in a neonatal intensive care unit.

Authors:  Julia Morinis; Jay Shah; Prashanth Murthy; Martha Fulford
Journal:  Paediatr Child Health       Date:  2011-06       Impact factor: 2.253

2.  Infected breast milk associated with late-onset and recurrent group B streptococcal infection in neonatal twins: a genetic analysis.

Authors:  Arnaud Gagneur; Geneviève Héry-Arnaud; Séverine Croly-Labourdette; Gisèle Gremmo-Feger; Sophie Vallet; Jacques Sizun; Roland Quentin; Didier Tandé
Journal:  Eur J Pediatr       Date:  2008-12-16       Impact factor: 3.183

Review 3.  Molecular epidemiology of mastitis pathogens of dairy cattle and comparative relevance to humans.

Authors:  Ruth N Zadoks; John R Middleton; Scott McDougall; Jorgen Katholm; Ynte H Schukken
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-04       Impact factor: 2.673

4.  Prevalence of oropharyngeal group B Streptococcus colonization in mothers, family, and health care providers.

Authors:  Kristina Roloff; Gohar Stepanyan; Guillermo Valenzuela
Journal:  PLoS One       Date:  2018-09-28       Impact factor: 3.240

5.  Streptococcus agalactiae Infects Glial Cells and Invades the Central Nervous System via the Olfactory and Trigeminal Nerves.

Authors:  Anu Chacko; Ali Delbaz; Indra N Choudhury; Tanja Eindorf; Megha Shah; Christopher Godfrey; Matthew J Sullivan; James A St John; Glen C Ulett; Jenny A K Ekberg
Journal:  Front Cell Infect Microbiol       Date:  2022-02-24       Impact factor: 5.293

Review 6.  Breast Milk: A Meal Worth Having.

Authors:  Anoud Duale; Parul Singh; Souhaila Al Khodor
Journal:  Front Nutr       Date:  2022-01-26

Review 7.  Breast milk and Group B streptococcal infection: vector of transmission or vehicle for protection?

Authors:  Kirsty Le Doare; Beate Kampmann
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.